Payment overview · 2025
General Payments
$557.17
18 reported records · 9 companies
Healthcare provider profile · identity verified
James D Carey, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HARTSVILLE, TN · NPI 1053854083
Verified facts
What the public records show
CMS Open Payments records show James D Carey, APN received $557.17 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $222.35 | 39.9% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $158.49 | 28.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.03 | 6.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.38 | 5.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.67 | 5.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.63 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.86 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.95 | 3.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.81 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $557.17 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $195.73 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $158.49 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $137.22 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $110.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.67 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 137 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
137 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 445 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 89 |
| Losartan Potassium | Losartan Potassium | 288 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 68 |
| Omeprazole | Omeprazole | 245 | 68 |
| Simvastatin | Simvastatin | 241 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 56 |
| Gabapentin | Gabapentin | 217 | 39 |
| Furosemide | Furosemide | 214 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 53 |
| Glimepiride | Glimepiride | 194 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 184 | 52 |
| Potassium Chloride | Potassium Chloride | 179 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 162 | 27 |
| Prednisone | Prednisone | 153 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 35 |
| Carvedilol | Carvedilol | 151 | 43 |
| Metformin Hcl Er | Metformin Hcl | 148 | 39 |
| Eliquis | Apixaban | 146 | 20 |
| Metformin Hcl | Metformin Hcl | 141 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 45 |
| Ozempic | Semaglutide | 137 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 28 |
| Trazodone Hcl | Trazodone Hcl | 133 | 34 |
| Allopurinol | Allopurinol | 120 | 28 |
| Meloxicam | Meloxicam | 116 | 35 |
| Montelukast Sodium | Montelukast Sodium | 116 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 37 |
| Atenolol | Atenolol | 112 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 28 |
| Spironolactone | Spironolactone | 92 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 23 |
| Ezetimibe | Ezetimibe | 76 | 20 |
| Famotidine | Famotidine | 74 | 20 |
| Baclofen | Baclofen | 70 | 30 |
| Alprazolam | Alprazolam | 69 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 11 |
| Pregabalin | Pregabalin | 66 | suppressed |
| Azithromycin | Azithromycin | 59 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | suppressed |
| Glipizide | Glipizide | 57 | 15 |
| Buspirone Hcl | Buspirone Hcl | 56 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 17 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 15 |
| Finasteride | Finasteride | 54 | 16 |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 12 |
| Clonidine Hcl | Clonidine Hcl | 51 | 13 |
| Cephalexin | Cephalexin | 50 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | suppressed |
| Nifedipine Er | Nifedipine | 50 | 15 |
| Celecoxib | Celecoxib | 49 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 38 |
| Glipizide Er | Glipizide | 48 | 12 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 35 |
| Dexamethasone | Dexamethasone | 44 | 17 |
| Estradiol | Estradiol | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Amoxicillin | Amoxicillin | 42 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Methylprednisolone | Methylprednisolone | 42 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 23 |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Glyburide | Glyburide | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Nabumetone | Nabumetone | 37 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 34 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 19 |
| Topiramate | Topiramate | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | 12 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 12 |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 12 |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $557.17 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AZMIRO, BREZTRI, CAPLYTA, FANAPT, FARXIGA, HETLIOZ, Korlym, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error